Advancement in Polymer-based Carrier for DNA Vaccine
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
A novel strategy that has the potential to solve the drawbacks of the present conventional vaccines is the development of DNA vaccines. DNA vaccines offer a versatile and adaptable platform for treating a wide variety of diseases, as immunization targets may be easily adjusted by altering the gene sequences encoded in the plasmid DNA delivered. Due to their ability to elicit both humoral and cellular immune responses, their stability, and the ease with which they may be produced, plasmid DNA vaccines are quickly becoming the vaccine of choice, they are frequently safer than conventional vaccinations. Despite the highly encouraging outcomes of ongoing clinical trials, these vaccines' immunogenicity is compromised by a few factors. The use of various vaccine delivery techniques, the use of various polymer-based carriers, and the use of adjuvants are some of the several approaches that might be examined to better the immunogenicity of DNA vaccines made from plasmids. These advancements taken together might allow plasmid DNA vaccines to be successfully used in clinical settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 29(2023), 26 vom: 30., Seite 2062-2077 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goyal, Priyanshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants |
|---|
| Anmerkungen: |
Date Completed 13.10.2023 Date Revised 18.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1381612829666230830105758 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361426852 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361426852 | ||
| 003 | DE-627 | ||
| 005 | 20231226085120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612829666230830105758 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361426852 | ||
| 035 | |a (NLM)37644794 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goyal, Priyanshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advancement in Polymer-based Carrier for DNA Vaccine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2023 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a A novel strategy that has the potential to solve the drawbacks of the present conventional vaccines is the development of DNA vaccines. DNA vaccines offer a versatile and adaptable platform for treating a wide variety of diseases, as immunization targets may be easily adjusted by altering the gene sequences encoded in the plasmid DNA delivered. Due to their ability to elicit both humoral and cellular immune responses, their stability, and the ease with which they may be produced, plasmid DNA vaccines are quickly becoming the vaccine of choice, they are frequently safer than conventional vaccinations. Despite the highly encouraging outcomes of ongoing clinical trials, these vaccines' immunogenicity is compromised by a few factors. The use of various vaccine delivery techniques, the use of various polymer-based carriers, and the use of adjuvants are some of the several approaches that might be examined to better the immunogenicity of DNA vaccines made from plasmids. These advancements taken together might allow plasmid DNA vaccines to be successfully used in clinical settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19. | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a adjuvants | |
| 650 | 4 | |a plasmid DNA vaccine | |
| 650 | 4 | |a polymer | |
| 650 | 4 | |a virus like particles | |
| 650 | 7 | |a Vaccines, DNA |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 700 | 1 | |a Malviya, Rishabha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 29(2023), 26 vom: 30., Seite 2062-2077 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:26 |g day:30 |g pages:2062-2077 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1381612829666230830105758 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 26 |b 30 |h 2062-2077 | ||